ClinicalTrials.Veeva

Menu
M

Mid Atlantic Retina Specialists | Hagerstown, MD

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Aflibercept
APL-2
Bevacizumab
GB-102
Sunitinib Malate
Runcaciguat

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 11 total trials

A Single-Arm Study of Aflibercept 8 mg Dosed in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (ELARA)

This study is researching an experimental drug called aflibercept 8 mg, referred to as "study drug". The study is focused on participants with nAMD a...

Enrolling
Neovascular Age-Related Macular Degeneration
Diabetic Macular Edema
Drug: Aflibercept 8 mg

Researchers are looking for a better way to treat people who have macular edema secondary to retinal vein occlusion (RVO).In people with RVO, a blood...

Enrolling
Macular Edema Secondary to Retinal Vein Occlusion
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
Drug: Sham
Locations recently updated

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling
Wet Age-related Macular Degeneration
WetAMD
Biological: Aflibercept (EYLEA®)
Genetic: ABBV-RGX-314 Dose 2

Trial sponsors

Jaeb Center for Health Research logo
A
Bayer logo
AbbVie logo
C
G
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems